Dublin, Jan. 26, 2024 (GLOBE NEWSWIRE) -- The "Stem Cell Therapy Market by Type (Allogeneic, Autologous), Cell Source (Adipose Tissue, Bone Marrow, Placenta/Umbilical Cord), Therapeutic Application (Musculoskeletal, Wounds, Surgeries, Inflammatory, Autoimmune, Cardiovascular) - Global Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.
The global stem cell therapy market is on the threshold of significant expansion, projected to reach a valuation of USD 615 million by 2028, from USD 286 million in 2023. This remarkable growth, charting a compound annual growth rate (CAGR) of 16.5% during the forecast period, is predominantly catalyzed by vigorous development activities pursued by key industry players seeking breakthroughs in the treatment of a variety of disease conditions through stem cell therapies. The therapeutic applications of stem cell therapy include musculoskeletal, wounds, surgeries, inflammatory and autoimmune diseases, and cardiovascular conditions.
Allogeneic Stem Cell Segment Continues Dominance
The allogeneic stem cell sector has held a substantial share in the stem cell therapy market in recent years. The potential to create multiple therapy doses from a single cell source gives allogeneic stem cell therapy a significant edge in terms of economic viability and streamlined production, cementing its supremacy within the market.
Bone Marrow-derived MSCs Segment Exhibits Notable Growth
With segmentation based on cell sources, the adipose tissue-derived mesenchymal stem cells (MSCs) commanded a prominent market share in 2022. Nonetheless, bone marrow-derived mesenchymal stem cells (MSCs) are increasingly preferred for a multitude of stem cell therapies owing to their ready availability and fewer in-vitro processing time requirements.
Asia Pacific Market Poised for Rapid Expansion
Geographical analysis of the stem cell therapy market illustrates a burgeoning Asia Pacific market, poised to grow robustly due to proactive governmental approvals and strategic alliances within the industry. Countries like South Korea are at the forefront, as exemplified by noteworthy collaborations such as the joint venture between Reyon Pharmaceutical and Therabest to advance NK cell therapy for solid cancers.
Key Attributes
| Report Attribute | Details |
| No. of Pages | 197 |
| Forecast Period | 2023-2028 |
| Estimated Market Value (USD) in 2023 | $286 Million |
| Forecasted Market Value (USD) by 2028 | $615 Million |
| Compound Annual Growth Rate | 16.5% |
| Regions Covered | Global |
Companies Mentioned
- Allosource
- Anterogen Co. Ltd.
- Athersys, Inc.
- Biorestorative Therapies, Inc.
- Brainstorm Cell Limited
- Cellular Biomedicine Group
- Corestem, Inc.
- Gamida Cell
- Holostem Terapie Avanzate Srl
- Hope Biosciences
- JCR Pharmaceuticals Co. Ltd.
- Kangstem Biotech Co. Ltd.
- Medipost
- Mesoblast Ltd.
- Nuvasive, Inc.
- Orthofix Medical Inc.
- Personalized Stem Cells
- Pharmicell Co. Ltd.
- Pluristem Therapeutics Inc.
- Regrow Biosciences Pvt. Ltd.
- Rti Surgical
- Smith+Nephew
- Stempeutics Research Pvt. Ltd.
- Takeda Pharmaceutical Company Limited
- Viacyte, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/ytbcs4
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
